This means that passive immunization with tau antibodies is usually a viable therapeutic goal and that the CSF amount of p-tau262/356 or from the microtubule binding area (MTBD) can serve as a handy biomarker of tau pathology to watch tau therapeutics in scientific trials.They demonstrated this romantic relationship with equally pathological specim